Posted by Michael Wonder on 14 Apr 2026
Travere Therapeutics announces full FDA approval of Filspari (sparsentan), the first and only approved medicine for FSGS
13 April 2026 - Travere Therapeutics today announced that the US FDA has approved Filspari (sparsentan) to reduce proteinuria in adult and paediatric patients aged 8 years and older with focal segmental glomerulosclerosis without nephrotic syndrome.
Filspari is the first and only medicine approved by the FDA for the treatment of FSGS, marking its expansion beyond IgA nephropathy into a second rare kidney disease.
